Based Review of GLP-1/GIP Agonists for Fitness and Wellness ProfessionalsGilbert, AZ, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The ...
Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback